Table 1.
Summary of alterations of E-cadherin and β-catenin in a series of 50 gastric tumours.
| Tumour | Stage | Type | Grade | LOH | E-cad gene mutations | Aberrant mRNA | E-cad | β-cat | |
| Sample | at 16q22.1 | and polymorphisms | of E-cad | IHC | IHC | ||||
| 1 | T3N3 | diff | + | IVS1+6T→C | - | +/- | ++/-∇ | ||
| 3 | T3N1 | squ | G1 | + | IVS4+10C→G | ND | - | +/- | |
| 17 | T3N1 | diff | ND | GTG(Val)→GTC(Val) at cd832 | ND | - | - | ||
| 23 | met | + | GCC(Ala)→ACC(Thr) at cd592* | ND | +++/- | +++/- | |||
| 43 | T3N2 | diff | + | - | - | - | +++/- | ||
| 50 | T3N1 | diff | - | IVS1+6T→C | - | ++/- | ++/- | ||
| 165 | T3N1 | int | G3 | ND | - | - | +++/- | +++/-∇ | |
| 174 | T3N2 | int | G3 | - | - | ND | +++/- | ++/- | |
| 193 | T3N2 | int | G3 | + | - | ND | -/+++ | -/++ | |
| 200 | T3N1 | int | G2 | - | IVS4+10C→G | - | ++/- | +++/- | |
| 231 | T3N0 | mi | G3 | + | - | - | ++/- | ++/-∇ | |
| 283 | T3N0 | int | G3 | ND | - | ND | ++/- | ++/- | |
| 287 | T3N1 | int | G2 | + | - | - | -/+ | ++/- | |
| 294 | T3N1M1 | mi | G4 | + | GCC(Ala)→ACC(Thr) at cd592♦ | - | ++/- | ++/-∇ | |
| 304 | T3N3 | int | G2 | - | - | - | -/+++ | +/- | |
| 308 | T3N1 | int | G2 | + | - | - | +++/- | ++/- | |
| 314 | T3N1 | diff | - | CAC(His)→CAT(His) at cd632 | - | +++/- | ++/-∇ | ||
| GGC(Gly)→GGT(Gly) at cd865 | |||||||||
| 360 | T2N1 | int | G3 | + | IVS4+10C→G | +♣ | ++/- | +/- | |
| 369 | met | + | - | +♣ | +++/- | +++/- | ++/- | ||
| 433 | T3N1 | mi | G3 | - | IVS4+10C→G | - | -/++ | -/+ | |
| 435 | T2N0 | int | G3 | + | - | - | -/+++ | -/++ | |
| 443 | T2N0 | int | G4 | - | - | - | +++/- | +++/- | |
| 451 | T4N0 | int | G2 | ND | - | ND | +++/- | ++/- | |
| 474 | T3N1 | int | G3 | ND | - | ND | - | +/- | |
| 493 | T3N1 | int | G3 | + | - | - | -/+++ | +/- | |
| 503 | T3N1 | int | G3 | ND | - | - | - | +++/- | |
| 556 | T3N2 | int | G2 | - | IVS1+6T→C | ND | ++/- | +/- | |
| 5'UTR-71C→G | |||||||||
| 568 | T3N2 | mi | G3 | + | - | +♣ | ++/- | ++/- | |
| 612 | T3N0 | int | G2 | ND | IVS4+10C→G | - | +++/- | +/- | |
| AAC(Asn)→AAT(Asn) at cd751 | |||||||||
| 636 | T3N1 | diff | + | IVS4+10C→G | ND | +++/- | +++/-∇ | ||
| 650 | T2N0M1 | int | G2 | + | - | ND | -/+ | ++/- | |
| 675 | T2N0 | mi | G3 | + | IVS4+10C→G | - | +/- | ++/-∇ | |
| 676 | T3N1 | int | G2 | + | - | - | +++/- | -∇ | |
| 680 | T3N1 | mi | G3 | + | IVS1+6T→C | - | ++/- | ++/- | |
| AAC(Asn)→AAT(Asn) at cd751 | |||||||||
| 694 | T3N1 | int | G1 | + | - | - | +++/- | +++/- | |
| 717 | T3N1 | int | G3 | + | - | +♣ | -/+++ | +++/- | |
| 726 | T2N1 | int | G2 | + | IVS4+10C→G | - | -/+++ | ++/- | |
| 728 | T3N0 | int | G2 | + | GCC(Ala)→ACC(Thr) at cd592♦ | - | -/+++ | ++/- | |
| 729 | T3N1 | int | G1 | - | IVS1+6T→C | - | -/+++ | +++/- | |
| 732 | T2N1 | int | G3 | + | - | - | -/+++ | +++/- | |
| 735 | T4N3 | diff | ND | AAC(Asn)→AAT(Asn) at cd751 | - | +++/- | +++/-∇ | ||
| 738 | T3N2 | diff | + | - | - | - | -∇ | ||
| 750 | met | ND | AAC(Asn)→AAT(Asn) at cd751 | +♣ | ++/- | +++/- | |||
| 755 | T2N1 | int | G2 | ND | - | +♥ | +++/- | ++/- | |
| 808 | T3N0 | int | G1 | + | ACG(Thr)→ACA(Thr) at cd251 | +♠ | +++/- | ++/- | |
| 811 | T2N1 | int | G2 | + | - | - | +++/- | -/+ | |
| 832 | T3N2 | int | G2 | + | - | - | +++/- | +++/-∇ | |
| 855 | T3N2 | int | G2 | + | - | - | +++/- | +++/- | |
| 875 | T3N2 | int | G2 | - | IVS4+10C→G | ND | +++/- | +++/- | |
| 904 | T2N0 | int | G3 | + | IVS4+10C→G | - | -/+++ | ++/- | |
| Useful | 30 | 3 | 7 | 21 | 14 | ||||
| Total | 40 | 50 | 38 | 50 | 50 | ||||
| % | 75 | 6 | 18 | 42 | 28 |
T, tumour (size and invasiveness); N, node (degree of metastasis); M, metastasis; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; G4, not differentiated; diff, diffuse (degree of differentiation=G4); mi, mixed; int, intestine; met, metastatic tumour probably from stomach tumour; squ, squamous epithelial; LOH, loss of heterozygosity; E-cad, E-cadherin; β-cat, β-catenin; IHC, immunohistochemistry; cd, codon; UTR, untranslated region; +, positive LOH, aberrant E-cad mRNA, E-cad and β-cat IHC;-, negative LOH, E-cadherin gene mutation, aberrant E-cad mRNA, E-cad and β-cat IHC; ND, not determined or not done; +/-, ++/- and +++/-, more than 50% cells positive; -/+, -/++ and -/+++, more than 50% cells negative; *, somatic mutation; ♦, germline mutation; ♣, insertion of intron 7 between exons 7 and 8, stop codon 374; ♥, deletion of last 72 bases of exon 7, exon 8 and first 124 bases of exon 9, stop codon 322; ♠, deletion of exons 8 and 9; deletion of last 84 bases of exon 8, stop codon 358; ∇, these samples also showed cytoplasmic staining for β-catenin IHC.